Lachlan Hay Hor-Hay. (Maybe "hey" is an American only idiom not used by Australian English speakers.)
There must be an underlying motivation for this story. I'll pick apart at it. It's an absolutely ungoogleable search to locate.
I entered my information for a free trial to obtain access but have not heard anything back yet.
https://pink.pharmamedtechbi.com/PS120803/Interview-Clinuvel-A-Company-That-Does-The-Unusual
It's disappointing to hear that the FDA NDA filing won't happen in 1H 17. Now, they're saying hopefully by year-end.
I didn't realize that the individual country reviews would be as onerous, as well. I knew price had to be agreed upon, but it looks like there's much more involved, including the costs and resources involved with setting up the distribution centers.
I'm somehow still optimistic, but this stock sure requires a hell of a lot of patience. We've been in this stock for nearly 12 years now and we have just barely doubled our money. I am not sure if our patience will last more than a couple of years without some major advances.
If Lachlan is still there now after all these years under Dr Wolgen or may appear to morphed as equal mostly, I think Lachlan is up to Dr Wolgen standards of play and probably transformed somewhat into Dr Wolgen style and characteristics. In some ways, for Lachlan to have survived the Dr Wolgen managing style, he may be even more suitable a personality to deal with difficulties in people in the organization and outside the organization a more diplomatic manner.
Dr Wolgen could control most all in the Clinuvel organization and team strategy and call the plays, but he could not fire a inept EMA bureaucrat or the German referenced regulators and or collusion of insurance companies whom tried to end Clinuvel.